{"id":205,"date":"2009-01-24T05:33:59","date_gmt":"2009-01-24T10:33:59","guid":{"rendered":""},"modified":"2022-01-22T13:24:59","modified_gmt":"2022-01-22T18:24:59","slug":"multicenter-investigation-of-the-opioid-antagonist-nalmefene-in-the-treatment-of-pathological-gambling","status":"publish","type":"post","link":"https:\/\/www.internetandpsychiatry.com\/wp\/topics\/compulsive-gambling\/multicenter-investigation-of-the-opioid-antagonist-nalmefene-in-the-treatment-of-pathological-gambling\/","title":{"rendered":"Multicenter investigation of the opioid antagonist nalmefene in the treatment of pathological gambling"},"content":{"rendered":"<p>Grant JE, Potenza MN, Hollander E, Cunningham-Williams R, Nurminen T, Smits G, Kallio A. <em><br \/>Am J Psychiatry<\/em>. 2006 Feb;163(2):303-12.<\/p>\n<p> <strong>OBJECTIVE:<\/strong> Pathological gambling is a disabling disorder experienced by  approximately 1%-2% of adults and for which there are few empirically  validated treatments. The authors examined the efficacy and tolerability of the  opioid antagonist nalmefene in the treatment of adults with pathological  gambling.<br \/>\n<!--more--><br \/>\n<br \/> <strong>METHOD:<\/strong> A 16-week, randomized, dose-ranging, double-blind,  placebo-controlled trial was conducted at 15 outpatient treatment centers  across the United States between March 2002 and April 2003. Two hundred  seven persons with DSM-IV pathological gambling were randomly assigned  to receive nalmefene (25 mg\/day, 50 mg\/day, or 100 mg\/day) or placebo.  Scores on the primary outcome measure (Yale-Brown Obsessive  Compulsive Scale Modified for Pathological Gambling) were analyzed by  using a linear mixed-effects model.<br \/><strong>RESULTS:<\/strong> Estimated regression  coefficients showed that the 25 mg\/day and 50 mg\/day nalmefene groups had  significantly different scores on the Yale-Brown Obsessive Compulsive Scale  Modified for Pathological Gambling, compared to the placebo group. A total  of 59.2% of the subjects who received 25 mg\/day of nalmefene were rated as  &#8220;much improved&#8221; or &#8220;very much improved&#8221; at the last evaluation, compared  to 34.0% of those who received placebo. Adverse experiences included  nausea, dizziness, and insomnia.<\/p>\n<p> <strong>CONCLUSIONS:<\/strong> Subjects who received  nalmefene had a statistically significant reduction in severity of pathological  gambling. Low-dose nalmefene (25 mg\/day) appeared efficacious and was  associated with few adverse events. Higher doses (50 mg\/day and 100  mg\/day) resulted in intolerable side effects.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Grant JE, Potenza MN, Hollander E, Cunningham-Williams R, Nurminen T, Smits G, Kallio A. Am J Psychiatry. 2006 Feb;163(2):303-12. OBJECTIVE: Pathological gambling is a disabling disorder experienced by approximately 1%-2% of adults and for which there are few empirically validated treatments. The authors examined the efficacy and tolerability of the opioid antagonist nalmefene in the [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[8],"tags":[],"class_list":["post-205","post","type-post","status-publish","format-standard","hentry","category-compulsive-gambling","has-post-title","has-post-date","has-post-category","has-post-tag","has-post-comment","has-post-author",""],"builder_content":"","_links":{"self":[{"href":"https:\/\/www.internetandpsychiatry.com\/wp\/wp-json\/wp\/v2\/posts\/205","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.internetandpsychiatry.com\/wp\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.internetandpsychiatry.com\/wp\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.internetandpsychiatry.com\/wp\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.internetandpsychiatry.com\/wp\/wp-json\/wp\/v2\/comments?post=205"}],"version-history":[{"count":1,"href":"https:\/\/www.internetandpsychiatry.com\/wp\/wp-json\/wp\/v2\/posts\/205\/revisions"}],"predecessor-version":[{"id":3613,"href":"https:\/\/www.internetandpsychiatry.com\/wp\/wp-json\/wp\/v2\/posts\/205\/revisions\/3613"}],"wp:attachment":[{"href":"https:\/\/www.internetandpsychiatry.com\/wp\/wp-json\/wp\/v2\/media?parent=205"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.internetandpsychiatry.com\/wp\/wp-json\/wp\/v2\/categories?post=205"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.internetandpsychiatry.com\/wp\/wp-json\/wp\/v2\/tags?post=205"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}